Anti-PHAP I (IN) Antibody (11082)
$445.00
| Host | Quantity | Applications | Species Reactivity | Data Sheet | |
|---|---|---|---|---|---|
| Rabbit | 100ug | ELISA,WB,ICC,IF | Human, Mouse, Rat |  |
Overview
Product Name Anti-PHAP I (IN) Antibody (11082)
Description Anti-PHAP I (IN) Rabbit Polyclonal Antibody
Target PHAP I (IN)
Species Reactivity Human, Mouse, Rat
Applications ELISA,WB,ICC,IF
Host Rabbit
Clonality Polyclonal
Isotype IgG
Immunogen Synthetic peptide corresponding to amino acids near the carboxy terminus of human PHAP I (accession no. P39687).
Properties
Form Liquid
Concentration Lot Specific
Formulation PBS, pH 7.4.
Buffer Formulation Phosphate Buffered Saline
Buffer pH pH 7.4
Format Purified
Purification Purified by peptide immuno-affinity chromatography
Specificity Information
Specificity This antibody recognizes human and mouse PHAP I (32kDa). The sequence of rat PHAP I is identical to human PHAP I.
Target Name Acidic leucine-rich nuclear phosphoprotein 32 family member A
Target ID PHAP I (IN)
Uniprot ID P39687
Alternative Names Acidic nuclear phosphoprotein pp32, pp32, Leucine-rich acidic nuclear protein, LANP, Mapmodulin, Potent heat-stable protein phosphatase 2A inhibitor I1PP2A, Putative HLA-DR-associated protein I, PHAPI
Gene Name ANP32A
Gene ID 8125
Accession Number NP_006296.1
Sequence Location Nucleus, Cytoplasm, Endoplasmic reticulum. Note=Translocates to the cytoplasm during the process of neuritogenesis (By similarity). Shuttles between nucleus and cytoplasm.
Biological Function Multifunctional protein that is involved in the regulation of many processes including tumor suppression, apoptosis, cell cycle progression or transcription (PubMed:16341127, PubMed:11360199, PubMed:18439902, PubMed:10400610). Promotes apoptosis by favouring the activation of caspase-9/CASP9 and allowing apoptosome formation (PubMed:18439902). In addition, plays a role in the modulation of histone acetylation and transcription as part of the INHAT (inhibitor of histone acetyltransferases) complex. Inhibits the histone-acetyltranferase activity of EP300/CREBBP (CREB-binding protein) and EP300/CREBBP-associated factor by histone masking (PubMed:11830591). Preferentially binds to unmodified histone H3 and sterically inhibiting its acetylation and phosphorylation leading to cell growth inhibition (PubMed:16341127). Participates in other biochemical processes such as regulation of mRNA nuclear-to-cytoplasmic translocation and stability by its association with ELAVL1 (Hu-antigen R) (PubMed:18180367). Plays a role in E4F1-mediated transcriptional repression as well as inhibition of protein phosphatase 2A (PubMed:15642345, PubMed:17557114). {PubMed:10400610, PubMed:11360199, PubMed:11830591, PubMed:15642345, PubMed:16341127, PubMed:17557114, PubMed:18180367, PubMed:18439902}.; (Microbial infection) Plays an essential role in influenza A, B and C viral genome replication (PubMed:32694517, PubMed:33045004, PubMed:33208942, PubMed:30666459). Mechanistically, mediates the assembly of the viral replicase asymmetric dimers composed of PB1, PB2 and PA via its N-terminal region (PubMed:33208942). Plays also an essential role in foamy virus mRNA export from the nucleus (PubMed:21159877). {PubMed:21159877, PubMed:30666459, PubMed:32694517, PubMed:33045004, PubMed:33208942}.
Research Areas Apoptosis
Background The PHAP proteins (tumor suppressor putative HLA-DR associated proteins) are important regulators of mitochondrial apoptosis. PHAP facilitates apoptosome- mediated caspase-9 activation to stimulate the mitochondrial apoptosis pathway. In addition, PHAP opposes both Ras- and myc- mediated cell transformation.
Application Images
Description Western Blot Validation in Human Raji Cell Lysate
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (A: 2 ug/mL, B: 4 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (A: 2 ug/mL, B: 4 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Description Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (2 ug/mL), PHAP I 11088 (1 ug/mL), and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (2 ug/mL), PHAP I 11088 (1 ug/mL), and beta-actin (1 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Description Western Blot Validation in Human Cell Lines
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Loading: 15 ug of lysates per lane. Antibodies: PHAP I 11082 (2 ug/mL), 1h incubation at RT in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.
Description Immunofluorescence Validation of PHAP I in Raji Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed Raji Cells labeling PHAP I with 11082 at 10 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
Immunofluorescent analysis of 4% paraformaldehyde-fixed Raji Cells labeling PHAP I with 11082 at 10 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red).
Description Immunocytochemistry Validation of PHAP I in Raji Cells
Immunocytochemical analysis of Raji cells using anti-PHAP I antibody (11082) at 2 ug/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
Immunocytochemical analysis of Raji cells using anti-PHAP I antibody (11082) at 2 ug/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin.
Description KD Validation of PHAPI in Human Breast Cancer Cells (Schafer et al., 2006)
Human Breast Cancer Cells (T47D cells) were transfected with control or PHAPI siRNA duplex. PHAPI was detected via Western Blot analysis by using the anti-PHAPI antibody. PHAPI expression was reduced after PHAPI siRNA knockdown.
Human Breast Cancer Cells (T47D cells) were transfected with control or PHAPI siRNA duplex. PHAPI was detected via Western Blot analysis by using the anti-PHAPI antibody. PHAPI expression was reduced after PHAPI siRNA knockdown.
Description Increased Expression Validation of PHAPI in Patient Samples of BreastTumor Tissue (Schafer et al., 2006)
PHAPI was overexpressed in all breast tumor samples of patients and human breast cancer cells (MDA-MB-453), but not in the normal breast tissue or human primary mammary epithelial cells (HMEC).
PHAPI was overexpressed in all breast tumor samples of patients and human breast cancer cells (MDA-MB-453), but not in the normal breast tissue or human primary mammary epithelial cells (HMEC).
Description Overexpression of PHAPI in Breast Cancer Cells (Schafer et al., 2006)
Western blot analysis with anti-PHAPI antibodies was performed for PHAPI in human cell lines from breast, prostate and lung. PHAPI was overexpressed in breast cancer cells when compared with normal cells (HMEC) whereas there were no significant differences in PHAPI expression in normal and cancer cells of either prostate or lung origin.
Western blot analysis with anti-PHAPI antibodies was performed for PHAPI in human cell lines from breast, prostate and lung. PHAPI was overexpressed in breast cancer cells when compared with normal cells (HMEC) whereas there were no significant differences in PHAPI expression in normal and cancer cells of either prostate or lung origin.
Description Induced Expression Validation of PHAPI/Anp32a in Atxn1 KO Mice (Sa´nchez et al., 2412)
Western blot analysis of PHAPI/Anp32a from the cerebellum of WT and Atxn1 KO mice. PHAPI expression was significantly increased (2 folds) in Atxn1 KO mice as compared to WT mice. The same effect was observed in PHAPI mRNA levels.
Western blot analysis of PHAPI/Anp32a from the cerebellum of WT and Atxn1 KO mice. PHAPI expression was significantly increased (2 folds) in Atxn1 KO mice as compared to WT mice. The same effect was observed in PHAPI mRNA levels.
Handling
Storage This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
Dilution Instructions Dilute in PBS or medium which is identical to that used in the assay system.
Application Instructions Immunoblotting: Use at 2-4 ug/mL.
Positive control: Raji cell lysate.
Immunocytochemistry: use at 2ug/mL.
These are recommended concentrations.
Enduser should determine optimal concentrations for their applications.
Positive control: Raji cell lysate.
Immunocytochemistry: use at 2ug/mL.
These are recommended concentrations.
Enduser should determine optimal concentrations for their applications.
References & Data Sheet
Data Sheet 
Download PDF Data Sheet
Download PDF Data Sheet